PortalPublikationenHER2 status of circulating tumor cells in patients with meta...

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.

Standard

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. / Fehm, Tanja; Müller, Volkmar; Aktas, Bahriye; Janni, Wolfgang; Schneeweiss, Andreas; Stickeler, Elmar; Lattrich, Claus; Löhberg, Christian R; Solomayer, Erich; Rack, Brigitte; Riethdorf, Sabine; Klein, Christoph; Schindlbeck, Christian; Brocker, Kerstin; Kasimir-Bauer, Sabine; Wallwiener, Diethelm; Pantel, Klaus.

in: BREAST CANCER RES TR, Jahrgang 124, Nr. 2, 2, 2010, S. 403-412.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Fehm, T, Müller, V, Aktas, B, Janni, W, Schneeweiss, A, Stickeler, E, Lattrich, C, Löhberg, CR, Solomayer, E, Rack, B, Riethdorf, S, Klein, C, Schindlbeck, C, Brocker, K, Kasimir-Bauer, S, Wallwiener, D & Pantel, K 2010, 'HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.', BREAST CANCER RES TR, Jg. 124, Nr. 2, 2, S. 403-412. <http://www.ncbi.nlm.nih.gov/pubmed/20859679?dopt=Citation>

APA

Fehm, T., Müller, V., Aktas, B., Janni, W., Schneeweiss, A., Stickeler, E., Lattrich, C., Löhberg, C. R., Solomayer, E., Rack, B., Riethdorf, S., Klein, C., Schindlbeck, C., Brocker, K., Kasimir-Bauer, S., Wallwiener, D., & Pantel, K. (2010). HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. BREAST CANCER RES TR, 124(2), 403-412. [2]. http://www.ncbi.nlm.nih.gov/pubmed/20859679?dopt=Citation

Vancouver

Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. BREAST CANCER RES TR. 2010;124(2):403-412. 2.

Bibtex

@article{57e5986e65db41d7966eb7483c56f5e7,
title = "HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.",
abstract = "There is a growing body of evidence that HER2 status can change during disease recurrence or progression in breast cancer patients. In this context, re-evaluation of HER2 status by assessment of HER2 expression on circulating tumor cells (CTCs) is a strategy with potential clinical application. The aim of this trial was to determine the HER2 status of CTCs in metastatic breast cancer patients comparing two CTC assays. A total of 254 patients with metastatic breast cancer from nine German university breast cancer centers were enrolled in this prospective study. HER2 status of CTCs was assessed using both the FDA-approved CellSearch{\textregistered} assay and AdnaTest BreastCancer . Using the CellSearch assay, 122 of 245 (50%) patients had 5 CTCs, and HER2-positive CTCs were observed in 50 (41%) of these patients. Ninety of 229 (39%) patients were CTC positive using AdnaTest BreastCancer, and HER2 positivity rate was 47% (42 of 90). The rate of breast cancer patients with HER2-negative primary tumors but HER2-positive CTCs was 32% (25 of 78) and 49% (28 of 57) using the CellSearch assay and AdnaTest BreastCancer, respectively. Considering only those patients who had CTCs on both tests (n = 62), concordant results regarding HER2 positivity were obtained in 50% of the patients (31/62) (P = 0.96, = -0.006). HER2-positive CTCs can be detected in a relevant number of patients with HER2 negative primary tumors. Therefore, it will be mandatory to correlate the assay-dependent HER2 status of CTCs to the clinical response on HER2-targeted therapies.",
author = "Tanja Fehm and Volkmar M{\"u}ller and Bahriye Aktas and Wolfgang Janni and Andreas Schneeweiss and Elmar Stickeler and Claus Lattrich and L{\"o}hberg, {Christian R} and Erich Solomayer and Brigitte Rack and Sabine Riethdorf and Christoph Klein and Christian Schindlbeck and Kerstin Brocker and Sabine Kasimir-Bauer and Diethelm Wallwiener and Klaus Pantel",
year = "2010",
language = "Deutsch",
volume = "124",
pages = "403--412",
journal = "BREAST CANCER RES TR",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

RIS

TY - JOUR

T1 - HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.

AU - Fehm, Tanja

AU - Müller, Volkmar

AU - Aktas, Bahriye

AU - Janni, Wolfgang

AU - Schneeweiss, Andreas

AU - Stickeler, Elmar

AU - Lattrich, Claus

AU - Löhberg, Christian R

AU - Solomayer, Erich

AU - Rack, Brigitte

AU - Riethdorf, Sabine

AU - Klein, Christoph

AU - Schindlbeck, Christian

AU - Brocker, Kerstin

AU - Kasimir-Bauer, Sabine

AU - Wallwiener, Diethelm

AU - Pantel, Klaus

PY - 2010

Y1 - 2010

N2 - There is a growing body of evidence that HER2 status can change during disease recurrence or progression in breast cancer patients. In this context, re-evaluation of HER2 status by assessment of HER2 expression on circulating tumor cells (CTCs) is a strategy with potential clinical application. The aim of this trial was to determine the HER2 status of CTCs in metastatic breast cancer patients comparing two CTC assays. A total of 254 patients with metastatic breast cancer from nine German university breast cancer centers were enrolled in this prospective study. HER2 status of CTCs was assessed using both the FDA-approved CellSearch® assay and AdnaTest BreastCancer . Using the CellSearch assay, 122 of 245 (50%) patients had 5 CTCs, and HER2-positive CTCs were observed in 50 (41%) of these patients. Ninety of 229 (39%) patients were CTC positive using AdnaTest BreastCancer, and HER2 positivity rate was 47% (42 of 90). The rate of breast cancer patients with HER2-negative primary tumors but HER2-positive CTCs was 32% (25 of 78) and 49% (28 of 57) using the CellSearch assay and AdnaTest BreastCancer, respectively. Considering only those patients who had CTCs on both tests (n = 62), concordant results regarding HER2 positivity were obtained in 50% of the patients (31/62) (P = 0.96, = -0.006). HER2-positive CTCs can be detected in a relevant number of patients with HER2 negative primary tumors. Therefore, it will be mandatory to correlate the assay-dependent HER2 status of CTCs to the clinical response on HER2-targeted therapies.

AB - There is a growing body of evidence that HER2 status can change during disease recurrence or progression in breast cancer patients. In this context, re-evaluation of HER2 status by assessment of HER2 expression on circulating tumor cells (CTCs) is a strategy with potential clinical application. The aim of this trial was to determine the HER2 status of CTCs in metastatic breast cancer patients comparing two CTC assays. A total of 254 patients with metastatic breast cancer from nine German university breast cancer centers were enrolled in this prospective study. HER2 status of CTCs was assessed using both the FDA-approved CellSearch® assay and AdnaTest BreastCancer . Using the CellSearch assay, 122 of 245 (50%) patients had 5 CTCs, and HER2-positive CTCs were observed in 50 (41%) of these patients. Ninety of 229 (39%) patients were CTC positive using AdnaTest BreastCancer, and HER2 positivity rate was 47% (42 of 90). The rate of breast cancer patients with HER2-negative primary tumors but HER2-positive CTCs was 32% (25 of 78) and 49% (28 of 57) using the CellSearch assay and AdnaTest BreastCancer, respectively. Considering only those patients who had CTCs on both tests (n = 62), concordant results regarding HER2 positivity were obtained in 50% of the patients (31/62) (P = 0.96, = -0.006). HER2-positive CTCs can be detected in a relevant number of patients with HER2 negative primary tumors. Therefore, it will be mandatory to correlate the assay-dependent HER2 status of CTCs to the clinical response on HER2-targeted therapies.

M3 - SCORING: Zeitschriftenaufsatz

VL - 124

SP - 403

EP - 412

JO - BREAST CANCER RES TR

JF - BREAST CANCER RES TR

SN - 0167-6806

IS - 2

M1 - 2

ER -